<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156541">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02095392</url>
  </required_header>
  <id_info>
    <org_study_id>H55-14</org_study_id>
    <nct_id>NCT02095392</nct_id>
  </id_info>
  <brief_title>Effects of Soluble Phosphate in Humans</brief_title>
  <official_title>The Effect of Soluble Phosphate in Combination With Different Calcium Doses on Calcium and Phosphorus Metabolism in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Jena</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Jena</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study was conducted to investigate the effect of soluble phosphate  in combination with
      different calcium doses on calcium and phosphorus metabolism and further physiological
      parameters in healthy subjects. The main aim of the study is to investigate the influence of
      a soluble phosphate supplementation on the fasting blood phosphate concentration and the
      dependency of an additional calcium intake.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Fasting phosphate concentration in blood</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Calcium and phosphorus metabolism</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>parameters of phosphate and calcium metabolism (1,25-OHD; 25-OHD;FGF23;PTH)
parameters of bone formation and resorption (osteocalcin, P1NP, CTX)
minerals in plasma, faeces and urine</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>P1000/Ca0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>P1000/Ca500</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>P1000/Ca1000</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>P1000/Ca0</intervention_name>
    <description>22 subjects consume for 8 weeks a beverage enriched with phosphate  [1g phosphorus/d]</description>
    <arm_group_label>P1000/Ca0</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>P1000/Ca500</intervention_name>
    <description>22 subjects consume for 8 weeks a beverage enriched with phosphate [1 g phosphorus/d] and calcium [0,5 g calcium]</description>
    <arm_group_label>P1000/Ca500</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>P1000/Ca1000</intervention_name>
    <description>22 subjects consume for 8 weeks a beverage enriched with phosphate [1 g phosphorus/d] and calcium [1 g calcium]</description>
    <arm_group_label>P1000/Ca1000</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>all participants consume two weeks before intervention the beverage without phosphate and calcium</description>
    <arm_group_label>P1000/Ca0</arm_group_label>
    <arm_group_label>P1000/Ca500</arm_group_label>
    <arm_group_label>P1000/Ca1000</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age between 18-60 years

          -  physical health

        Exclusion Criteria:

          -  postmenopausal women

          -  kidney diseases

          -  diabetes mellitus

          -  metabolic diseases

          -  osteoporosis

          -  intake of dietary supplements

          -  pregnancy and lactation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Glei, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Friedrich-Schiller-University Jena, Institute of Nutrition, Department of Nutritional Toxicology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Friedrich-Schiller-University Jena, Institute of Nutrition, Department of Nutritional Toxicology</name>
      <address>
        <city>Jena</city>
        <state>Thuringia</state>
        <zip>07743</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 22, 2014</lastchanged_date>
  <firstreceived_date>March 17, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Jena</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Michael Glei</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>soluble phosphate</keyword>
  <keyword>phosphorus metabolism</keyword>
  <keyword>calcium metabolism</keyword>
  <keyword>bone metabolism</keyword>
  <keyword>human study</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
